69491-51-6Relevant academic research and scientific papers
Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl] piperidine series of histamine H3 receptor antagonists
Berlin, Michael,Ting, Pauline C.,Vaccaro, Wayne D.,Aslanian, Robert,McCormick, Kevin D.,Lee, Joe F.,Albanese, Margaret M.,Mutahi, Mwangi W.,Piwinski, John J.,Shih, Neng-Yang,Duguma, Luli,Solomon, Daniel M.,Zhou, Wei,Sher, Rosy,Favreau, Leonard,Bryant, Matthew,Korfmacher, Walter A.,Nardo, Cymbelene,West Jr., Robert E.,Anthes, John C.,Williams, Shirley M.,Wu, Ren-Long,Susan She,Rivelli, Maria A.,Corboz, Michel R.,Hey, John A.
, p. 989 - 994 (2007/10/03)
A novel series of histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine template displaying low CYP2D6 and CYP3A4 inhibitory profiles has been identified. Structural features responsible for the reduction of P450 activity, a typical liability of 4-substituted imidazoles, have been established.
Synthesis and mesomorphic properties of trans-[1,4-bis5-R-pyrimidin-2-yl]-cyclohexanes and 1,2-bis-(5-R-pyrimidin-2-yl)ethanes
Mikhaleva,Kuznetsova
, p. 310 - 315 (2007/10/03)
New trans-bis(5-R-pyrimidin-2-yl)-1,4-cyclohexanes and -1,2-ethanes (R = C7H15, C6H4OR1, where R1 = H, COCH3, C4H9, C5H11, C8/su
